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The issue of whether to treat all patients with mild hyper¬ 
tension (diastolic blood pressure = 90-110 mmHg) remains controversial 
despite the results of eight large-scale randomized clinical trials 
(RCTs). The most common medical problem in the adult population, mild 
hypertension contributes significantly to cardiovascular and there¬ 
fore overall morbidity and mortality. The status of mild hypertension 
as one of the larger problems in clinical therapy has prompted much 
comment on the as yet unresolved dilemma of treatment. The purpose 
of this thesis will be not only to explain how this controversy has 
come to exist, but also to determine whether a methodologic analysis 
of the data can help to resolve the dispute. In the introduction of 
this paper, I shall develop an historical framework of investigations 
determining the therapeutic efficacy of pharmacologic intervention 
in hypertensive disease, progressing from the more severe to the less 
severe forms of this disorder. Investigations studying milder forms 
of hypertension encountered substantial scientific challenges, not 
encountered in studies of severe hypertension, requiring the design 
and implementation of large multi-center randomized trials. In the 
latter part of the introduction, I shall comment on the advantages ■ 
of randomized clinical trials over observational studies, and conclude 
with a discussion of many of the issues involved in assessing the 
quality of an RCT (internal validity) and determining its applicability 




Despite the association of hypertension with cardiovascular 
disease, it was not until the introduction of ganglionic blocking 
agents by Paton and Zamais (1) in 1949 that investigators could 
determine whether pharmacologic reduction of arterial blood pressure 
would reduce the risk of developing cardiovascular complications. 
The earliest studies dealt with "malignant" (accelerated) hyper¬ 
tension. The untreated clinical course of this disease is well- 
characterized and highly uniform: 80-90% of patients die within 
the first year of presentation (2). Death is secondary to arteriolar 
damage and generally results from renal failure due to nephrosclerosis, 
though intracerebral hemorrhage and congestive heart failure are also 
common. In 1952, McMichael (3) demonstrated immediate "benefit 
from treatment" with hexamethonium in 4 of 7 patients with malignant 
hypertension. Unfortunately, further information as to outcome was 
not provided, and thus it is difficult to evaluate therapeutic 
efficacy. In addition, therapy was complicated by the need for sub¬ 
cutaneous administration, difficulties titrating the drug, and severe 
side effects. Among the reported side effects were postural hypo¬ 
tension, urinary retention, constipation, tremor, visual disturbances, 
and confusion. With the development of better oral ganglionic 
blocking agents, and with the addition of hydralazine and reserpine, 
several investigators in the late 1950s reported significant reduc¬ 
tions in short and long term morbidity among their treated patients 
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with accelerated hypertension (4,5,6,7). Similar studies were per¬ 
formed for "pre-malignant" (severe) hypertension. In addition to 
having markedly elevated blood pressures, all of these patients had 
evidence of serious end-organ disease (cardiac, renal, optic, 
central nervous system) by history, physical exam, or diagnostic 
tests. None of the patients had papilledema, hypertensive encephal¬ 
opathy, or rapidly deteriorating renal function, and most of the 
patients had diastolic blood pressures lower than patients with 
accelerated hypertension. In these studies, patients treated with 
anti-hypertensive therapy had a substantial reduction in morbidity 
during the 4-7 years of follow-up (8,9). All of these studies 
included small numbers of treated patients (range: 7-84), and none 
of the studies employed a concurrent, untreated control group. 
Rather, the patients' survival was compared to the known natural 
course of the disease. Despite the small size and inadequate design 
of these studies, the results were quickly embraced by clinicians 
because of the remarkable potential benefits which had been pre¬ 
viously unattainable. 
These more severe forms of hypertension were relatively 
easily defined; the patients were all at high risk with most patients 
following a rapid and relentless downhill course. Hence, any improve¬ 
ment with pharmacologic therapy was readily appreciated. As 
investigators turned to the study of unaccelerated ("benign") essen¬ 
tial hypertension, the problems of demonstrating the effectiveness 
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of therapy increased substantially. Though these patients were at 
some increased risk for developing cardiovascular disease, the risk 
of developing cardiovascular disease was highly variable and com¬ 
plications progressed slowly if at all. Since the outcome of an 
individual patient for a given period of observation was no longer 
predictable, the benefits of therapy could only be measured by 
comparing the incidence of death and morbid events in a treated 
population of hypertensive patients to that of a concurrently 
untreated by otherwise similar population of patients. The earliest 
studies, which were retrospective observational studies, proved to 
be inconclusive. In 1959, Leishman (10) reported his findings from 
a retrospective study of 402 patients who had been diagnosed as 
being hypertensive (diastolic blood pressure > 120 mmHg), At the 
discretion of their personal physicians, these patients with "benign" 
hypertension had either been started on pharmacologic therapy or 
been given no treatment at all. The period of time from the time 
of diagnosis ranged from 1 to 13 years. Leishman found a significant 
difference in mortality between these two groups of patients with 
nearly three times as many deaths in the group of patients not re¬ 
ceiving medical therapy. However, in a similar study, Perrera (11) 
compared the mortality rate in 29 matched pairs of patients with 
"benign" hypertension (diastolic pressure > 120 mmHg) and found no 
difference between those patients who had not received treatment and 
those who had. There were 16 deaths in each group. 
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Feeling that observational studies were inadequate to assess 
properly the therapeutic efficacy of anti-hypertensive agents in 
unaccelerated hypertension, the Veterans Administration Cooperative 
Group (12) initiated a prospective randomized clinical trial in 
1963. This study of 143 patients with "moderate" hypertension 
(diastolic blood pressure = 115-129 mmHg) was terminated early in 
1967, after only four years of follow-up, when highly significant 
results led investigators to conclude that it was unethical to con¬ 
tinue the trial. There were 27 morbid events including 4 deaths in 
the placebo group (39%) compared with 2 morbid events with no deaths 
in the actively treated group (3%). Morbid events included: aortic 
aneurysm, cerebral hemorrhage or thrombosis, retinopathy with or 
without papilledema, doubling of the Blood Urea Nitrogen I> 60 mg 
\ 100 cc 
persistent elevation of the diastolic blood pressure (> 140 mmHg), 
congestive heart failure, and myocardial infarction. These results 
were consistent with the statistically significant findings of two 
other, smaller, prospective randomized clinical trials in patients 
with a similar severity of hypertension (diastolic blood pressure > 
120 mmHg) (13,14). 
By this time, data from the Framingham Heart Survey (15) had 
suggested that people with mild hypertension (diastolic blood pres¬ 
sure = 90-115 mmHg) are at increased risk for developing cardio¬ 
vascular disease. The Framingham Study suggested not only that 
hypertensives are at increased risk of cardiovascular-related 
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morbidity and mortality, but also that the degree of risk is 
directly related to the systolic and diastolic pressures. This 
study, an epidemiologic investigation started in 1948, has followed 
over 5,000 adults biennially. Patients in the study are examined 
regularly for the development of cardiovascular disease as mani¬ 
fested by: coronary artery disease, myocardial infarction, 
congestive heart failure, cerebrovascular accident, claudication, 
sudden death, cardiovascular-related death, and death from all 
causes. Among the potential risk factors assessed in the study 
were: hypertension, serum cholesterol level, serum phospholipid 
level, relative body weight, smoking history, gender, race, and 
age. The investigators correlated the occurrence of cardiovascular 
events with the full range of diastolic and systolic pressures and 
as expected, the highest incidence of disease was in the hypertensive 
group (a diastolic pressure > 95 mmHg and a systolic pressure > 160 
mmHg). However, this increased risk was found to extend to some 
degree over the full range of diastolic and systolic pressures. The 
risk was greater in men than women at all levels of blood pressure 
and increased in both groups with increasing age. 
The dramatic benefits noted in the randomized clinical trials 
of moderate hypertension (diastolic blood pressure = 115-129 mmHg) 
led many physicians to believe that the benefits of anti-hypertensive 
therapy might extend to mild hypertension, and several studies have 
been performed in this group of patients. However, these large 
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prospective trials have had difficulties in administration, inter¬ 
pretation, and clinical application. Although patients with mild 
hypertension appear to be at some increased risk for developing 
cardiovascular disease, before attempting to treat all such patients 
it is imperative that we determine whether: 
(1) Pharmacologic intervention will indeed result in a_ 
significantly decreased risk for developing cardiovascular disease. 
Inherent in the mild hypertension trials is the assumption 
that pharmacologic lowering of the arterial blood pressure to 
"normotensive" levels will eliminate or at least diminish the rela¬ 
tive risks associated with the disorder and that the difference 
resulting from the compared treatments will be clinically substan¬ 
tial. It is not sufficient for these studies to look only at pro¬ 
portional risk reduction. For deciding issues in personal health 
care, the absolute risk reduction to be gained by treatment is also 
significant. For example, if treatment for a given disorder resulted 
in a proportional risk reduction of 50%, this might mean that the 
chances of suffering a morbid event were reduced from one in 10,000 
to one in 20,000, or it might mean that they were reduced from one 
in 10 to one in 20. When deciding whether treatment is indicated 
for each individual patient, the practicing physician must consider 
not just the proportional risk reduction, but the changes in absolute 
risks as well. 
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(2) The benefits of therapy will outweigh the hazards, 
inconvenience and expense. 
A second assumption investigators have made is that treatment 
with anti-hypertensive agents is virtually benign though there is 
remarkably little information, particularly quantitative data, on 
the incidence of adverse effects associated with anti-hypertensive 
therapy. Even the information concerning the short term side-effects 
of anti-hypertensive medications is largely descriptive and falls 
into 3 major categories: fluid and electrolyte abnormalities 
(e.g., postural hypotension, hypokalemia, hyperuricemia); cardiac 
and vasomotor dysfunction (e.g., congestive heart failure); and 
disturbances of the central nervous system (fatigue, depression, 
impotence). When one considers the more subtle adverse effects 
that might be associated with chronic therapy such as diminished 
functional capacity(e.g., beta-blocking agents), poorer quality of 
life, and long-range side-effects, the available information is 
largely of an anecdotal nature and is not adequate for use in 
clinical decision-making. 
(3) Risk factors other than level of blood pressure are 
equally or more important indicators for deciding who should and 
should not receive treatment. 
Diastolic blood pressure, a relatively simple value to deter¬ 
mine, provides useful information particularly in the asymptomatic 
patient. It is tempting to use this physical finding as a marker 
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by which all patients can be conveniently classified as either "nor- 
motensive" (those not requiring treatment) or "hypertensive" (those 
requiring treatment). But this is not enough, for such an approach 
fails to do justice to the complexity of the problem. Co-morbid 
clinical characteristics (such as age, gender, race, smoking, 
diabetes mellitus, and evidence of end-organ disease) are relevant 
to the development of cardiovascular disease and so must be taken 
into consideration when weighing issues of personal health. A 
study which fails to do so is incomplete and fails to provide 
the practicing physician with the information needed to make specific 
decisions for individual patients. 
The treatment question is made even more compelling by data 
from the National Health Survey of people in the United States 
between 18 to 74 years of age, which estimates that approximately 
26% of the adult population has a diastolic pressure greater than 
90 mmHg. Of people 45 years of age and older, approximately 35% of 
men and 29% of women have "mild hypertension" (diastolic blood 
pressure = 90-110 mmHg). Additionally, there is another 35% of the 
population with a diastolic pressure of 80-89 mmHg (16). 
Recognizing the importance of the problem, several groups of 
investigators performed studies to determine whether anti-hypertensive 
therapy is efficacious in mildly hypertensive patients. Many research 
strategies were available, but most researchers chose to employ pro¬ 
spective randomized clinical trials. Observational cohort studies 
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were generally considered to be inadequate to study this complex 
problem as such studies permit substantial bias (17,18). Since a 
crucial part of the assessment of therapeutic efficacy is the choice 
of the research strategy, I will now discuss why the RCT has come to 
be the accepted scientific "gold standard". 
Randomized clinical trials have an advantage over observational 
surveys in that they employ several experimental principles which 
help to minimize the occurrence of bias (19). The chief advantage 
of the RCT is the process of randomization, a method by which patients 
who have met admission criteria can be entered into a study and as¬ 
signed treatment in a purely random manner. In clinical practice, 
the choice of therapy is determined by both the physician and the 
patient. These preferences can introduce serious selection bias into 
a study however, by assigning patients with a particularly good (or 
poor) prognosis to one treatment modality or the other. The randomi¬ 
zation process helps to ensure that patients in the experimental 
group are prognostically equivalent to those in the compared group. 
There are several other important scientific principles intrinsic to 
the design of the RCT which must be mentioned. Two of the principles 
involve the establishment of criteria to exclude either patients 
with strong indications or contraindications to any of the treatments 
being studied or patients who are so ill that death occurs before 
randomization can take place. Two other principles are concerned 
with the analysis of data. Patients who later change their 
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randomized treatment (e.g., patients with mild hypertension receiv¬ 
ing placebos who are later switched to active anti-hypertensive 
medications because their blood pressure rises above pre-defined 
limits) can either be eliminated or, preferably, considered 
separately in the analysis. Lastly, the patients can be strati¬ 
fied according to pertinent pre-treatment characteristics so that 
the effects of treatment can be assessed separately among prog- 
nostically similar groups of patients. At the same time, 
stratification helps to compensate for any pre-treatment prognostic 
disparities that may have occurred in spite of the randomization 
process (20). 
The prospective randomized clinical trial is a method which 
has been developed to find answers to clinical questions while 
adhering to scientific experimental principles. A well-designed 
RCT must meet several requirements in each of three major areas: 
the establishment of the baseline state, the performance of the 
maneuver (the treatment phase), and the detection and analysis of 
outcome events (21,22). 
The Baseline State 
The investigators’ first responsibility is to define pre¬ 
cisely the disease in question by providing the diagnostic criteria 
used (e.g., the Veterans Administration Cooperative Study defined 
mild hypertension as a diastolic blood pressure range of 90-114 mmHg) 
(23). The population of patients which is entered into the study 
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must be described with particular attention given to not only the 
severity of the disease under study but also co-morbid risk factors 
that might influence outcome. This relevant information should be 
collected so that it will be available to stratify the patients into 
prognostic subgroups when it is time to analyze the data. 
Having fully described the study population, investigators 
must then ensure that the patients assigned to each of the compared 
treatments are at equal risk for developing outcome events. Ideally, 
the patients should be identical except for the therapeutic maneuver 
under study; since this is obviously not possible, random assign¬ 
ment of treatment is necessary to prevent selection bias. This 
process should be both blinded and strictly random. The assignment 
of treatment is not truly random if patients are assigned treatment 
by alternating: days of the week, admitted patients, admitting 
physicians, admitting hospital wards, etc, A physician could 
knowingly or unknowingly bias the results by withholding patients 
with a particularly poor (or good) prognosis until the "right" time 
when they would receive what the admitting physician considered the 
more desirable therapy (24), In addition, delays in the adminis¬ 
tration of treatment could in and of themselves influence the 
results. Though there are reported instances of physicians deli¬ 
berately attempting to select specific treatments for some of their 
patients (24), the main goal of blinded random allocation is to 
prevent unintended bias from entering into studies. The efficacy 
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of the randomization process should then be confirmed by examining 
the distribution of patients in the compared populations (22,25). 
Execution of the Therapeutic Maneuver 
Again, the first requirement is that the investigators define 
the compared treatments. The definitions should include a complete 
discussion of the experimental therapy as well as the compared 
treatment (23) (e.g., no treatment, type of placebo, etc.). 
Additionally, all ancillary therapy should be described and parti¬ 
cular emphasis should be given if it differs among the compared 
treatments, e.g., advice given to patients with mild hypertension 
regarding diet, smoking, exercise, and weight reduction (26). 
These co-maneuvers should be identical in the compared groups to 
prevent confusion when the results of the trial are later examined. 
The maneuver should be performed with an appropriate and equal level 
of skill (23). However, opinions can vary as to what is "appropriate". 
There has been much debate over whether treatment should be adminis¬ 
tered in such a way as to approximate common clinical practice or 
whether it should be administered in the best possible fashion. This 
dispute has been at issue in several studies, for example, those 
comparing the medical and surgical management of coronary artery 
disease (27,28). 
Regardless of whether treatment is deemed to be "appropriate", 
it must be administered with equal rigor. When possible, patients 
should be blinded as to the type of treatment they are receiving. 
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This is particularly important for the monitoring of the more sub¬ 
jective outcome events and adverse effects (22,23). The physicians 
should also be blinded. Since drug therapy requires regulation, 
studies must be designed to allow for "stepped" care so that dosage 
can be individualized. The results of the UGDP study on diabetes 
mellitus have been questioned because oral hypoglycemic agents 
were given in a fixed dosage to all patients with no attempt to 
regulate the blood glucose level (29). Similarly, a study on mild 
hypertension would be seriously flawed if the same anti-hyperten¬ 
sive medication were given in the same dose to all patients with 
no attempt to adjust treatment to the measured blood pressure. A 
drug regimen must be allowed to achieve its designed physiologic 
effect for it to have any chance of influencing outcome (23). 
Hence, in addition to providing "stepped care", the investigators 
should assess compliance with the chief therapeutic maneuver and 
all co-maneuvers. 
Detection and Analysis of Outcome Events 
The events chosen as the main outcome of an RCT must be 
suitably selected so that they are both clinically relevant and 
statistically countable (21); the range of events should encompass 
not only benefits of therapy but also possible adverse effects (23) 
This is not always easy however. If some of the chief effects of treat 
ment consist of subtle alterations in symptoms or functional 
capacity, or subjective changes in quality of life, it may be 
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difficult to quantify these data so that they can be statistically 
analyzed. The selection of outcome events is particularly impor¬ 
tant in the mild hypertension trials as these patients are generally 
healthy symptomless patients who are at low risk for dying or 
suffering morbid events such as myocardial infarction, cerebrovas¬ 
cular accident, or congestive heart failure (30). Failure to 
respond to assigned therapy should not necessarily be considered 
a trial end point. Patients in the mild hypertension studies who 
were removed from the trials because their diastolic pressure con¬ 
tinued to rise above the range for mild hypertension defined within 
the studies should not be considered as having had an outcome event 
regardless of their assigned treatment. Following the selection of 
outcome events, there must then be equal detection of end points 
in the patients receiving the compared treatments. All trial end 
points should then be reviewed by an independently blinded committee 
(22). 
The patients in each of the treatment populations should be 
stratified into prognostic subgroups according to clinical features 
which are relevant to the outcome events that have been selected. 
In the mild hypertension trials, pertinent clinical data might in¬ 
clude such risk factors as the degree of diastolic pressure eleva¬ 
tion, duration of pressure elevation, the presence of diabetes 
mellitus, a history of smoking, and evidence of end-organ disease 
by history, physical exam, or diagnostic tests (31). The results 
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of the therapeutic maneuver should then be presented for each of 
the prognostic strata rather than the study population as a whole. 
This will achieve a more effective and clinically meaningful com¬ 
parison of the benefits of treatment for patients at variable 
degrees of risk. Those patients lost to follow-up or withdrawn 
from the study must be included in the final analysis of data. 
They should be fully described, and the reason for their removal 
from the study documented (patient vs. investigator initiated). 
If there is a significant difference between the compared regimens 
in the number of patients who have left or been removed from a 
study, a reason should be sought; in any case, if the overall 
dropout rate exceeds 15% or the dropout rate is greater than the 
incidence of outcome event, the results of the study may be 
unreliable (22,23). 
The extrapolation of the results of any study concerned 
with clinical therapy is an inevitable problem, distinct from 
issues involved with assessing internal validity. If the patients 
in the study do not suitably represent the eligible population, 
then the reader may reject any subsequent findings as being ir¬ 
relevant to the patients that he/she sees in clinical practice 
(32). Investigators should provide evidence for having estimated 
the size of the trial population necessary to demonstrate a sta¬ 
tistically significant difference (at a stated level of significance, 
e.g., a = .05) between the compared treatments for the selected 
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outcome events. A description of population transfers should fol¬ 
low, beginning with an explanation of the manner in which the 
target population was identified and screened. The overall yield 
from the number of people screened to the number of patients 
eventually admitted into the trial should be included. A complete 
description of both the admission and rejection criteria should 
be provided so that the reader can obtain a clear picture of the 
patients studied in the trial. Lastly, a description of the eli¬ 
gible patients not entered into the trial should be included with 
specific reasons for their ineligibility (e.g., poor motivation). 
METHODS 
I have used several criteria for selecting papers for review 
in this thesis. The study had to be a prospective randomized 
clinical trial concerned with determining the efficacy of treatment 
in reducing morbidity and mortality in patients with mild hyper¬ 
tension. To facilitate the review, I have selected only those 
investigations which have been published in the English language 
literature. A computer-assisted search of the literature was per¬ 
formed identifying 86 potentially relevant articles published 
between 1968-1981. These included 13 (33-45) papers on 11 large- 
scale RCTs of mild hypertension, only eight (33-43) of which have 
been completed (see Table 1). Of the three incomplete trials, one, 
the Medical Research Council (MRC) (44) study in Great Britain, 
and a second, the European Working Party on Hypertension in the 
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Elderly (EWPHE) (45) study are ongoing trials. However, due pri¬ 
marily to problems with funding the project, the full-scale 
Veterans Administration-National Heart, Lung, and Blood Institute 
(VA-NHLBI) study was never implemented after the two-year feasibi¬ 
lity trial was completed. Pertinent preliminary studies (46-52), 
editorials, letters, and policy statements (30,53-63) accounted 
for 20 of the articles identified in the computer search. In 
addition, material cited in the reports of the RCTs has been col¬ 
lected and reviewed. Dr. H. Mitchell Perry of the VA-NHCBI group 
(64) and Dr. Edward Frohlich of the Hypertension Detection and 
Follow-up Program (65) were contacted in an effort to add any 
published or, as yet, unpublished data which might be of impor¬ 
tance to this review. The vast majority of papers identified by 
the computer search (53) were not suitable for this review, since 
these studies compared the pressure-lowering capacity of various 
drug regimens in mildly hypertensive patients. 
To evaluate the eight completed studies, I have developed 
a broad set of methodologic criteria for each of the three major 
areas critical to the design of an RCT. I will now present the 
methodologic standards and the operational criteria which I have 
developed to ensure that these methodologic standards are fulfilled. 
The purpose of applying these criteria to each of the trials is 
to ensure that the results are at the same time scientifically 
valid and clinically meaningful. 
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The methodologic standard and the criteria necessary to ful¬ 
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I have appraised each of the 8 completed studies (Table 1) to 
determine the degree to which each of these methodologic standards 
has been fulfilled. Though I have presented this exhaustive list 
of methodologic standards, in the review of each individual study 
I will focus on those standards which contribute most to understanding 
the deficiencies in experimental design which may have influenced 
the subsequent results. 
In an effort to examine all of the results in a standardized 
fashion, I have developed a list of outcome events which will be 
applied to each of the studies: 
(1) Death from all causes 
(2) Major morbid events: myocardial infarction,cerebrovascu¬ 
lar accident, congestive heart 
failure, dissecting aortic aneurysm. 
(3) Minor morbid events: left ventricular hypertrophy, evi¬ 
dence of renal failure, retinopathy, 
transient ischemic attacks. 
(4) Adverse effects: biochemical as well as physiologic, 
subjective changes in functional 
capacity and quality of life. 
While one can debate the "appropriateness" of any list of outcome 
events, I maintain that this systematic approach to evaluating the 
results of these many trials can provide useful information in terms 
of assessing the efficacy of anti-hypertensive therapy in preventing 




VETERANS ADMINISTRATION COOPERATIVE GROUP (33-35) 
Summary 
This trial was designed to determine whether anti-hyper¬ 
tensive therapy reduces cardiovascular-related morbidity in 
mildly hypertensive patients. In this study, the number of 
patients screened was not stated. Patients were selected from 
a hospitalized population; those with an average diastolic blood 
pressure of 90-114 mmHg on the fourth through sixth hospital day 
were eligible for admission to the study. Patients were exclud¬ 
ed from the study on the basis of: 1) evidence of complications 
of severe hypertension, e.g., hypertensive encephalopathy, 
cerebrovascular hemorrhage; 2) surgically treatable hypertension; 
3) unrelated terminal illness; 4) a demonstrated unwillingness 
to comply with assigned therapy. The investigators decided not 
to exclude all patients with end organ complications, since this 
would have restricted the size of the trial population, and more 
importantly, would have severely limited the general applicability 
of the results. Consequently, 58% of the 380 participants admitted 
to the trial had evidence of end organ disease. Additional 
characteristics of the study population are provided in Table 2. 
Whereas 186 subjects were randomized to receive the experimental 
regimen (see Table 3), 194 were randomized to the placebo group. 
The mean duration of follow-up was 3.3 years. A mean difference 
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in diastolic pressure of 18.6 mmHg was achieved between the com¬ 
pared groups in this study; this was the largest difference exhi¬ 
bited in any of the RCTs. Patients were allowed to continue in 
this trial untreated until their diastolic blood pressure exceeded 
124 mmHg on three consecutive visits. At such time, patients 
were designated as "treatment failures" and known active medica¬ 
tion was administered. There were 20 such treatment failures 
during the trial, all from the control group (10%). 
All trial end-points were reviewed by a blinded committee. 
There were 10 deaths (5.4%) in the actively treated group and 21 
deaths (10.8%) in the placebo group (see Table 5). The incidence 
of major events (myocardial infarction, congestive heart failure, 
cerebrovascular accident) was 4.8% in the treated group as compared 
with 14.8% in the placebo group (see Table 6). The data for minor 
end-points was incomplete. In addition to comparing the incidence 
of trial end-points between the treated and untreated groups, 
the investigators examined the rate of trial end-points and the 
effectiveness of treatment with respect to risk factors present 
at entry: cardiovascular-renal abnormalities (the prevalence of 
which was higher than in the general population of mildly hyper¬ 
tensive patients), degree of diastolic blood pressure elevation, 
and age. The majority of patients developing morbid events were 
in the older age group. There was nearly a three to one predilection 
for suffering a morbid event in those patients over 50 years of age 
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regardless of the assigned treatment. The presence of prior cardio¬ 
vascular damage greatly increased the risk for developing morbid 
events following randomization. The level of pre-randomization 
diastolic blood pressure was also found to contribute to the 
rate of trial end points. The effectiveness of treatment was evi¬ 
dent in those patients with a pre-randomization diastolic blood 
pressure greater than 104 mmHg. The incidence of outcome events 
was 32% (35) in the treated group as compared with 8% (8) in the 
placebo group. However, the difference in the incidence of outcome 
events between treated and placebo patients was less clearcut in 
those subjects with a pre-randomization diastolic pressure below 
this level (treated: placebo = 16% 114 outcome events] : 25% [21 
outcome events]). Indeed, these patients seemed to derive little 
benefit from treatment unless they had cardiovascular abnormalities 
at entry or were over 50 years of age. 
Over 40% of the patients in the treated group experienced 
hypotensive side effects shortly after starting treatment. The 
authors attributed this high incidence to the fact that the 
protocol called for all patients assigned to the group to begin 
treatment with a triple-drug regimen rather than a single anti¬ 
hypertensive agent. Two treated patients were removed from the 
trial because they developed reactions presumed to be due to drug 
toxicity. In addition, 29 patients (control: treated = 4,5%: 11%) 
were removed from study protocol because of complaints of 
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gastrointestinal disturbances, depression, fatigue, impotence, and 
gout. The investigators also examined biochemical side-effects and 
found a significantly increased incidence of hypokalemia and hyper¬ 
uricemia in the treated population. The dropout rate was similar 
in the two groups and averaged 15% during the period of follow-up. 
The authors concluded that treatment is definitely indicated 
in all patients with a diastolic blood pressure greater than 104 mmHg 
and in patients with a diastolic blood pressure of 90-104 mmHg who 
are at increased risk because of age or evidence of cardiovascular 
disease. They added that the possibility of side effects — 
symptomatic or biochemical — must be weighed against the benefit 
to be expected from treating hypertensive patients who are at low 
risk (diastolic blood pressure of 90-104 mmHg and without other 
risk factors). 
Commentary 
The investigators did find a statistically significant 
difference in cardiovascular-related morbidity between treated 
and untreated patients in this, the first, study of mild hyper¬ 
tension (diastolic blood pressure = 90-114 mmHg); however, there 
are many methodologic deficiencies in this study. The target pop¬ 
ulation was poorly identified — rather than screening the general 
population, the investigators chose to recruit the study population 
from people who had maintained elevations in blood pressure (dias¬ 
tolic blood pressure of 90-114 mmHg) while hospitalized. Smith (58) 
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has argued that this range of diastolic blood pressure in a hospi¬ 
talized patient corresponds more closely to a pressure of 100-120 inmHg 
when measured in an outpatient setting. While it is important not 
to exclude patients with prior cardiovascular disease, this study 
had an especially large proportion of such patients (58%) chiefly 
because subjects were selected from a hospitalized pool of patients 
rather than the general population. Unfortunately, through 
demographic data was presented, data for co-morbid risk factors 
such as hyperlipidemia, smoking, and diabetes mellitus was not 
provided. The selected population was further limited in that un¬ 
cooperative or unreliable patients were eliminated during a pre¬ 
randomization observation period. Lastly, women were not 
considered in this study. 
Treatment was randomly assigned and administered in a 
double-blind manner in this placebo-controlled study. Both the 
placebo and the experimental regimen were clearly defined and 
compliance with the assigned regimen was monitored. Although the 
design of the trial was such that alerations could be made in the 
therapeutic regimen, the initial administration of a triple-agent 
regimen to all subjects in the experimental group far from approxi¬ 
mate contemporary clinical practice. This protocol may have been 
partially responsible for the high incidence of hypotensive side 
effects seen in the actively treated group. Ancillary therapy was 
neither prescribed nor monitored. Despite limiting mild 

32 
hypertension to patients with a diastolic blood pressure of 90-114 
mmHg, patients in the control group were allowed to maintain a dia¬ 
stolic blood pressure of up to 124 mmHg before active therapy was 
instituted, i.e. patients in the control group were allowed to progress 
to a more severe form of hypertension with its associated greater 
risk but continued to be compared with patients in the actively 
treated group whose blood pressure had been maintained at or below 
entry levels. The authors noted that pharmacologic intervention had 
prevented the elevation in blood pressure beyond 124 mmHg seen in 
approximately 10% of the control group, however, close supervision 
could have achieved the same end. 
The investigators developed an inclusive list of well-defined 
trial end points. However, their attempt to separate outcome events 
into those attributable to hypertension and those attributable to 
atherosclerosis was somewhat artificial. One of the chief strengths 
of this study was that attack rates and therapeutic effectiveness 
were analyzed according to multiple prognostic factors: age, degree 
of diastolic blood pressure elevation, and evidence of cardiovascular 
abnormalities. While it is of interest to assess the influence of 
these factors either individually or in combination, it must be noted 
that stratification of the patient population into small subgroups 
increases the likelihood of large errors in observed rates due to 
random fluctuation, especially when the trial population is small as 
it was in this study. Prognostic stratification can provide useful 
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information, however, particularly in a heterogeneous population where 
the patients are at highly variable degrees of risk. Indeed strati¬ 
fication of this trial population by entry blood pressure suggested 
that there was no statistically significant difference in cardio¬ 
vascular-related morbidity between treated and untreated patients 
with a diastolic blood pressure less than 104 mmHg. 
While the authors provided data for the incidence of acute 
side-effects of treatment, the long-term follow-up was inadequate. 
Over 11% of the patients in the actively treated group were with¬ 
drawn from treatment due to serious side-effects. Unfortunately, 
this trial did not consider subjective changes in functional 
capacity or the quality of life, subtle changes which may have con¬ 
tributed to the nearly 15% drop-out rate. 
UNITED STATES PUBLIC HEALTH TRIAL (36) 
Summary 
In this study, the eligible population was selected from among 
1600 screened patients "said to have an elevated blood pressure" (36). 
The screening process yielded 389 subjects (24%) between the ages of 
21-55 with a diastolic pressure of 90-114 mmHg (while not receiving 
anti-hypertensive therapy). Admission criteria included; no evi¬ 
dence of end-organ disease (e.g., renal insufficiency, retinopathy, 
left ventricular hypertrophy) by history, physical exam, or para- 
clinical studies; and no evidence of co-morbid risk factors such as 
diabetes mellitus and hyperlipidemia. Forty-one percent of the 

34 - 
subjects had a history of treated hypertension. The admitted trial 
study group (see Table 2) was randomly assigned to receive either 
active treatment (193), consisting of chlorthiazide and rauwolfia 
serpentina, or placebo (196) and was then followed systematically 
for an average period of 7 years (see Table 3), Treated patients 
achieved a mean reduction in diastolic blood pressure of 10 mmHg 
which was maintained throughout the trial; in contrast, there was 
no mean change in the diastolic blood pressure in those patients 
receiving the placebo (see Table 4). There were 4 deaths during 
the trial (2 in each regimen) and 13 major morbid events with 6 in 
the treated group and 7 in the control population. The incidence 
of minor events (retinopathy, cardiomegaly, left ventricular 
hypertrophy, transient ischemic attacks, evidence of renal failure) 
was not evenly distributed however (active: placebo = 9.8%: 20.8%) 
When a patients blood pressure increased to levels of 130 mmHg or 
greater, he/she was classified as a "treatment failure" and started 
on active therapy; 12 such cases occurred in the placebo group as 
compared to none in the actively treated group. Though not well 
characterized 23(5.9%) participants were withdrawn from the study 
because of "drug intolerance" — 19 in the actively treated group 
and 4 in the placebo group. The overall drop-out rate was 33.9% 
but there was very little difference between the compared treatments 
The authors of the study concluded that careful follow-up 
with dietary management and control of other risk factors (e.g., 
smoking) was a viable alternative to pharmacologic intervention. 
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given the small degree of risk associated with this disorder and 
the failure of pharmacologic therapy to protect against athero¬ 
sclerotic disease. 
Commentary 
In this trial, there was no difference between treated and 
untreated subjects in the incidence of deaths or cardiovascular- 
related morbidity. There was a greater frequency of minor events 
in the untreated group, but the difference was not statistically 
significant and the detection of these "softer" end points is more 
readily biased. The validity of the findings of this trial are 
enhanced by the fact that allocation of patients was random and 
that treatment was administered in a double-blind fashion. The 
compared regimens were well-described and compliance with the 
assigned regimen was regularly followed. A disadvantage of this 
study is that the experimental protocol was relatively inflexible 
with no provisions mentioned for altering dosage or choice of 
medication; this may have contributed to the high incidence of 
drug-related side-effects. 
Patients in the placebo group were allowed to continue 
without active treatment until their diastolic blood pressure 
exceeded 130 mmHg (on three consecutive visits), despite evidence 
from earlier studies which had shown that patients with a diastolic 
pressure of 115-130 mmHg clearly benefit from treatment (12-14). 
Thus, the design of this study clearly violated the principles of 
sound clinical practice. Nevertheless, allowing patients in the 
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placebo group to continue untreated with a diastolic pressure of up 
to 130 mmHg should have enhanced the likelihood of detecting a 
difference between the two groups, yet no difference was found. 
The selection of outcome events was reasonably thorough and 
all events were reviewed by a blinded committee. However, the 
study gave inadequate attention to the issue of side-effects men¬ 
tioning only that 5.9% of patients were withdrawn from their 
assigned regimen due to "drug intolerance". There was no reported 
attempt to look for changes in functional capacity or quality of 
life. Though there was only a minimal difference in the incidence 
of withdrawals/drop-outs between the compared treatments, un¬ 
detected adverse effects of treatment may have contributed to the 
particularly high drop-out rate. 
VETERANS ADMINISTRATION — NATIONAL HEART, LUNG, AND 
BLOOD INSTITUTE TRIAL (37) 
Summary 
This two year feasibility trial was performed to determine 
whether a large population of mildly hypertensive asymptomatic 
patients could be identified, enlisted, and maintained on protocol 
for an adequate period of follow-up. The protocol employed in the 
feasibility trial was essentially the same as that which was to be 
used in the full-scale study. To be eligible for admission, sub¬ 
jects had to meet the following criteria: a consistent elevation 
of diastolic blood pressure (85-105 mmHg), an absence of 
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demonstrable cardiovascular disease, and a willingness to comply 
with study protocol. Subjects were required to be between 21-50 
years of age. Over 118,000 people were screened for mild hyper¬ 
tension at various locations in the community (e.g., factories, 
shopping centers); 1012 subjects (.86%) were eventually enrolled 
in the study. The most common reason for ineligibility was 
"normotension" (diastolic pressure less than 85 mmHg) — 88% of 
all people screened. Accepted patients were randomly assigned 
to treatment in this placebo-controlled trial and followed for 
two years. Their pre-treatment characteristics are provided in 
Table 2. Therapy was administered in a double-blind fashion 
according to a three step regimen as presented in Table 3. 
Ancillary measures were not discussed. The difference in dia¬ 
stolic blood pressure maintained between those patients in the 
experimental group and those in the compared group was similar to 
the difference achieved in other studies. At four months the 
difference in mean diastolic blood pressure was 3 mmHg, but by 
eight months the difference was 8 mmHg. 
Only 2 deaths (.4%) occurred during the study; both were 
in the treated group. There were an additional 5 major morbid 
events (treated: placebo = .4%: .6%). Although the complete 
data were not provided, the authors noted that preliminary analysis 
suggested that minor morbid events were more common in the treated 
population of patients. "Significant hypertension" was considered 
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to have developed whenever the diastolic blood pressure exceeded 
110 mmHg on four successive visits or 120 mmHg on two successive 
visits. This occurred in seven subjects all of whom were in the 
control group and active treatment was instituted for these patients. A 
total of 1303 side-effects were recorded for the actively treated 
group in contrast to 693 in the placebo group. There was a 
significantly increased (> 3 times) incidence of impotence, 
insomnia, asthenia, and nasal stuffiness in the experimental 
group suggesting that these side-effects were drug-related. 
Addtionally, there were significantly more asymptomatic biochemical 
abnormalities (e.g., hypokalemia, hyperuricemia) in the actively 
treated group (treated: placebo = 176: 8). The investigators 
recognized that pharmacologic anti-hypertensive therapy may exert 
a considerable influence on the quality of life. Despite efforts 
to quantify or "harden" this data, they were unable to make an 
adequate measurement. The drop-out rate in this two-year study was 
14%. 
The authors conclusions consisted of recommendations for the 
full-scale study. Because they found no difference in mortality or 
morbidity between the compared groups after two years of follow-up, 
they suggested that the full-scale trial: 1) have a longer period 
of follow-up — 5-10 years; 2) accept patients with a higher range 
of diastolic blood pressure — 85-115 mmHg; 3) accept patients with 
cardiovascular abnormalities. The last two recommendations were 
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made with the idea of increasing the overall incidence of outcome 
events and, additionally, to make the study population more repre¬ 
sentative of the general population of mild hypertensives. The in¬ 
vestigators further suggested that all future studies make a more 
serious attempt to consider the adverse consequences of treatment 
including subtle changes in the quality of life and the incidence 
of long-term side-effects. 
Comment ary 
In this study with a follow-up period of two years, there was 
no difference in mortality or morbidity between treated and untreated 
patients. The excellent design of this trial helps to ensure the 
scientific validity of the results. The target population was 
identified, and all population transfers were well-defined. Treat¬ 
ment in this placebo-controlled trial was assigned randomly and 
administered in a double-blind fashion. The compared populations 
had similar pre-treatment characteristics, thus confirming that the 
allocation process was effective. Both the experimental regimen 
and the placebo were well-described and provisions were made to 
adjust the therapeutic regimen as pressure-considerations or side- 
effects warranted. Patients with increasing blood pressures were 
handled appropriately in this study. When subjects sustainted an 
elevated blood pressure higher than the stated upper limit accepted 
for mild hypertension, active treatment with known pharmacologic 
agents was instituted. 
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A wide-range of outcome events was considered: death, 
cardiovascular-related morbidity, and adverse effects of treatment. 
Death and major morbid events were compared and found to be similar 
in the treated and untreated groups, but minor events were incom¬ 
pletely characterized. It was suggested however, that minor 
events may have been more common in the treated group. One of the 
strengths of this RCT is its rigorous approach to evaluating the 
potential adverse consequences of anti-hypertensive treatment. The 
investigators considered both biochemical and symptomatic side- 
effects. Of all outcome events considered, it was only for the 
adverse reactions to treatment that the authors found a statistically 
significant difference between the compared groups (with more adverse 
effects among treated patients). In addition, this was the only 
study which attempted to quantify "soft" data such as subjective 
changes in quality of life or functional capacity. Unfortunately, 
the investigators encountered many difficulties and were unable to 
satisfactorily gather this information. 
CHELMSFORD GROUP (38) 
Summary 
All patients screened in the Chelmsford Group Trial were 
referred to the clinic by their general practitioners. To be 
eligible for admission, it was required that subjects: be less 
than 50 years of age, maintain a diastolic blood pressure of 90-110 
mmHg, and be free of symptoms or complications attributable to 
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hypertension. Two hundred and thirty-three patients satisfied these 
criteria and were admitted to the trial. Their entry characteristics 
are provided in Table 2. Patients were assigned in alternate 
blocks of five to either the active (111) or the control group 
(122). Patients in the active group received anti-hypertensive 
medications in a "stepped fashion". By comparison, those in the 
control group received no treatment whatsoever but were followed at 
equally frequent intervals (see Tables 3-4). Any subject in the 
control group who developed and maintained levels of diastolic 
pressure of 110 mmHg or more was started on active therapy. There 
were 16 such patients (35%). 
Duration of follow-up ranged from 1 to 11 years with an 
average period of observation of 5.5 years. The mean difference in 
diastolic blood pressure maintained between the compared groups was 
not made clear. 
There were no deaths in either group during the trial. 
However, there were a total of 22 major morbid events with 6(5,4%) 
in the treated group and 16(13.2%) in the control group — the 
difference is not statistically significant. Unfortunately, minor 
events as well as adverse effects of treatment were not considered. 
The drop-out rate was slightly more than 7%. 
The authors concluded that patients with asymptomatic mild 
hypertension require close supervision particularly if anti¬ 




This study had negative findings with no statistically sig¬ 
nificant difference in outcome between treated and untreated 
patients with asymptomatic mild hypertension. Furthermore, the 
non-significant trend in major morbid events (treated: untreated = 
5.4%: 13.2%) which prompted the investigators to suggest that 
treatment might be of some benefit in these patients could be 
attributable to the design of this study. This trial has serious 
deficiencies in each of the major areas comprising the RCT which 
compromise its scientific validity. 
The population targeted for study in this trial was poorly 
identified. Evidently, physicians referred patients with suspected 
hypertension to a screening clinic where serial blood pressures were 
recorded. (The number of referrals was not stated.) Patients with 
a diastolic blood pressure in the defined mild range were eligible 
for admission. The selection criteria were designed to ensure that 
only subjects with minimal pre-treatment risk were included, so that 
patients over 50 years of age or those with evidence of end-organ 
disease were excluded; however, it is unclear whether patients with 
other risk factors for cardiovascular disease (e.g., smoking, hyper¬ 
lipidemia, diabetes mellitus) were included because the trial 
population was inadequately described. The most serious shortcomings, 
those most responsible for allowing bias to enter the trial, were 
in the execution of the therapeutic maneuver. Treatment was assigned 

- 43 
by systematic allocation rather than by a strictly random process. 
Also, the administration of treatment was not blinded as patients 
in the control group were untreated. There was no mention of 
ancillary treatment measures for either group. The results of 
treatment in terms of blood pressure control were not clear; the 
difference in the mean diastolic pressure achieved between the two 
groups was not stated. The study was limited to the analysis of 
"serious events", i.e. congestive heart failure, myocardial 
infarction, and stroke. Minor end-points and adverse effects of 
treatment were altogether ignored. 
The small difference in trial end-points during this trial 
between the treated and untreated groups does not support the 
authors’ suggestion that patients with asymptomatic mild hyper¬ 
tension might benefit from treatment, particularly since the design 
of the trial provided ample opportunity for bias to influence the 
results in favor of the treated group. 
HYPERTENSION DETECTION AND FOLLOW-UP PROGRAM (HDFP) (39-40) 
Summary 
In the HDFP trial, outcome for subjects receiving systematic 
anti-hypertensive treatment in program centers ("Stepped Care") was 
compared to that for persons referred to existing community medical 
care ("Referred Care"). The trial was designed to detect a 40% 




An effort was made to identify hypertensives in the general 
population. A population-based screening of nearly 160,000 adults 
from 14 communities in the United States yielded 10,400 subjects 
(6.8%) for study. To be eligible for admission, participants, 
30-69 years of age, had to have a mean diastolic blood pressure 
greater than 90 mmHg — patients already being treated for hyper¬ 
tension or those with evidence of end-organ disease were not 
excluded. (Those selected for study are described in Table 2.) 
In addition to demographic data, information was provided in regard 
to the incidence of patients with a history of treated hypertension 
(25%), evidence of end-orgam disease (5-7%), or co-morbid risk 
factors (e.g., diabetes mellitus, hypercholesterolemia, smoking). 
The subjects were randomized to "Stepped Care" (3903) or "Referred 
Care" (3922) with stratification by entry blood pressure: Stratum 
I = 90-104 mmHg; Stratum II = 105-115 mmHg; Stratum III = 115+ mmHg. 
Over 70% of the patients admitted for study were in Stratum I. 
Since the purpose of this methodologic review is to analyze studies 
of mild hypertension, further discussion will be lmited to the 
population of patients in Stratum I who were well-matched at entry. 
Patients assigned to the "Stepped Care" regimen received a 
free, standardized program of anti-hypertensive therapy at special 
clinics established by the HDFP. In an attempt to achieve uninter¬ 
rupted therapy, regular clinic attendance and compliance with 
treatment were monitored. The protocol (see Table 3) allowed for 
changes in the drug dosage or regimen to minimize the adverse effects 
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of treatment while maintaining control of blood pressure. In 
addition to pharmacologic therapy, counseling was offered regularly 
in regard to the importance of diet, exercise, weight reduction, 
and smoking. The HDFP investigators felt that the results of the 
VA trials on moderate and mild hypertension made it "inappropriate" 
to use placebos in large numbers of hypertensives across the full 
range of severity to be encountered in this community based trial. 
Thus, it was decided not to deny pharmacologic therapy to any 
patient. Subjects randomized to the "Referred Case" group were 
referred for treatment to their usual sources for medical care. 
(Special efforts were made to ensure that patients with severe hyper¬ 
tension would receive treatment.) Whereas patients in the "Stepped 
Care" group were seen in HDFP clinics at least every four months, 
patients in the "Referred Care" group were seen only once a year. 
Due to the design of this trial, patients in both groups were 
eligible to receive anti-hypertensive treatment, and the mean dif¬ 
ference in diastolic pressure maintained between the compared 
groups during the 5 years of the trial was only 5 mmHg. However, 
there was consistently a greater proportion of patients receiving 
pharmacologic treatment in the "Stepped Care" group ("Stepped Care: 
Referred Care" = 66-75%: 40-54%), and more subjects in the "Stepped 
Care" group maintained a diastolic pressure in the "normotensive 
range" — less than 90 mmHg. ("Stepped Care: Referred Care" = 
60%: 40%). It was not stated whether the failure of patients in 
the "Referred Care" group to receive treatment was unintentional 
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(e.g., inadequate follow-up, poor compliance) or a result of 
deliberate medical policy. Patients were permitted to continue 
in the "Referred Care" group without treatment until their diastolic 
pressure exceeded 115 mmHg (not 104 mmHg), At this point, special 
efforts were made to ensure that these patients would receive 
treatment. However, "Referred Care" patients were seen in HDFP 
clinics only once a year so that the ability to detect patients 
with elevated pressures was somewhat limited. 
Death was selected as the primary end-point in the HDFP 
trial. The investigators found a statistically significant dif¬ 
ference (P < .01) between the compared groups in the number of 
deaths during the 5 year follow-up period (SC: RC = 5.9%: 7.4%), 
There were 26% fewer cardiovascular deaths in "Stepped Care" than 
in "Referred Care" subjects and 13% fewer non-cardiovascular deaths. 
The authors failed to find a significant reduction in mortality in 
each subgroup when subjects were stratified by race and/or sex. 
For example, in white women there was less than a 5% reduction in 
all-cause mortality for those subjects in the "Stepped Care" group. 
In addition, for men and women less than 50 years of age, no benefit 
was seen. 
In an effort to obtain objective evidence of non-fatal 
secondary end points, the investigators collected data reflecting 
target organ damage (e.g., electrocardiogram, serum creatinine 




The authors suggested that the experience of the Hypetension 
Detection and Follow-up Program demonstrated an ability to identify 
a high percentage of hypertensive persons in the general population 
and maintain most of those detected in a long-term control program. 
The results of the trial led the investigators to conclude that 
the systematic effective management of hypertension has a great 
potential for reducing mortality for the large number of people 
with elevated blood pressure in the general population, including 
those with mild hypertension. 
Commentary 
This trial was designed for the purposes of determining 
whether: 1) a substantial proportion of all hypertensives in the 
general population could be identified; 2) those patients found to 
be hypertensive could be maintained on long-term anti-hypertensive 
therapy aimed at reducing blood pressure to nomotensive levels; 
3) a systematic approach to anti-hypertensive therapy (Stepped 
Care) would be more effective in reducing risk of five year mor¬ 
tality for all hypertensive adults compared to routine medical care 
available in the community (Referred Care). The purpose of this 
trial was not to prove that patients with hypertension (including 
mildly hypertensive patients) benefit from anti-hypertensive 
therapy. The investigators had been persuaded by the evidence in 
earlier studies that patients with any degree of diastolic pressure 
elevation are at increased risk and benefit from treatment; therefore. 
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they felt that it would be unethical to deny pharmacologic therapy 
to such patients. Consequently, they developed a scheme whereby 
therapy would be potentially available to all subjects -- partici¬ 
pants were randomized to either "Stepped Care" or "Referred Care" 
The investigators estimated, however, that fewer patients in the 
"RC" group would receive treatment because of uncertainty in the 
general medical community on the value of treating mild hyper¬ 
tension and a less systematic approach to treatment (e.g., less 
frequent follow-up, poorer compliance). Indeed, fewer patients 
in the "RC" group did recieve treatment. However, because 
patients in this group were treated outside the study, the type 
of care they received, particularly with regard to ancillary therapy, 
remains somewhat of an unknown and subject to a high degree of 
variability. Several other design consequences followed from the 
decision not to have a placebo control group: 
1) It was going to be more difficult to detect a significant 
difference in outcome atrributable to this risk factor given that the 
difference in the mean diastolic pressure would be attenuated by 
treatment of a large proportion of members in the "RC" group. 
Systematic ancillary therapy of co-risk factors for subjects in 
the "SC" group should have further limited the authors willingness 
to ascribe differences in outcome to the small differences in mean 




2) Death from all causes was designated as the sole end¬ 
point of this trial. As "SC" subjects were seen more frequently, 
it was decided that it would be improper to compare the incidence 
of morbid events (e.g., episodes of congestive heart failure, 
stroke, myocardial infarction) because prevention, and more im¬ 
portantly detection, of these outcome events might be related to 
how frequently subjects were observed. As a consequence, an im¬ 
portant consideration — morbidity — was omitted. 
3) The incidence of adverse effects of treatment could not 
be compared. In a study involving large numbers of often young 
people being exposed to pharmacologic events for long periods of 
time, it is unacceptable not to consider side-effects. The 
adverse consequences of treatment must be considered as well as 
the potential benefits. 
Nonetheless, the authors found a statistically significant 
difference in mortality between the two groups. They emphasized 
that the proportional risk reduction for members of the "SC" group 
was 20%, however, the absolute difference in mortality was small — 
1.5%. The benefits of the "SC" regimen were not limited to the 
prevention of cardiovascular deaths (proportional risk reduction = 
26%) as there was a 13% reduction in non-cardiovascular deaths. 
This finding would seem to indicate that the differences in mor¬ 
tality rate observed between the two groups was due to factors 
other than anti-hypertensive therapy. Possible explanations for 
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better outcome in the "Stepped Care" group might include: 1) the 
SC group was a healthier population at baseline (e.g., due to in¬ 
effective randomization); 2) the SC group received superior 
general medical care. In addition, the benefits of "Stepped 
Care" were not evenly distributed; white women and all subjects 
under 50 years of age failed to experience reduced mortality 
despite the lower pressures achieved through "Stepped Care". Over 
25% of the patients admitted to this study were already on anti¬ 
hypertensive therapy and thus, if left untreated, would have had 
more severe hypertenstion than their entry pressure suggested. 
Additionally, approximately 5% of the trial population had evi¬ 
dence of cardiovascular disease at the time of entry. It would be 
important to further analyze the data to see if benefit from 
treatment was restricted to these patients at increased risk.* 
It would also be helpful to examine the data dividing the patients 
into subgroups on the basis of entry diastolic pressure: 90-94 
mmHg, 95-99 mmHg, and 100-104 mmHg. 
*In a presentation to the American College of Cardiology in March 
of 1980, one of the investigators, Jeremiah Stamler, M.D., pre¬ 
sented the findings of subsequent analyses indicating that mor¬ 
tality was over three times higher in those with target-organ 
damage at entry than in those without it; in addition it was higher 
in the 25% of patients who entered the trial already on anti¬ 
hypertensive therapy. Unfortunately, this information is not 





In identifying the potential study population, the investi¬ 
gators attempted to screen all men living in Oslo between the ages 
of 40 to 49 years (~ 2500). A response rate of 65% produced 
16,200 men for screening of whom 785 (5%) were eventually ran¬ 
domized. Unlike most of the trials, this study incorporated both 
the systolic and diastolic blood pressure in defining mild hyper- 
tenstion: a systolic pressure of 150-179 mmHg or a diastolic 
pressure of 95-110 mmHg. As a result, over 12% of the study popu¬ 
lation had a diastolic blood pressure less than 90 mmHg. Two 
hundred and fifty-seven men who would have been eligible for 
admission to the study on the basis of their blood pressure were 
excluded by a rather extensive list of rejection criteria: a his¬ 
tory of previously treated hypertension, evidence of cardiovascular 
disease, coincident malignant or chronic illness, evidence of 
target organ damage (e.g., electrocardiographic findings consistent 
with cardiac abnormalities), ethanol abuse, or social maladjust¬ 
ment . 
Accepted patients were randomized to receive active treat¬ 
ment (406) or no treatment at all (379). The experimental 
regimen began with a diuretic to which either methyldopa or pro¬ 
pranolol could be added in variable dosage (see Table 3). A 
statistically significant difference between the two groups of 
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10 mmHg in mean diastolic pressure was maintained throughout the 
5 year period of observation (see Table 4). Over the course of 
the study there were 19 deaths which were evenly distributed 
between the two groups (see Table 5). The total number of major 
morbid events was 20(2.6%) with 8 events (20.0%) occurring in 
the treated group as compared with 12(3.2%) in the untreated 
group. There was a similar incidence of minor morbid events 
(treated: untreated = 1.6%: 3.2%). There was no significant 
difference in mortality or in the overall incidence of cardio¬ 
vascular events between treated and untreated participants. 
However, when the investigators stratified the study population 
on the basis of pre-treatment blood pressure into "high-risk" 
(diastolic pressure > 100 mmHg) and "low-risk" groups (diastolic 
pressure < 11 mmHg), they found there was a non-significant 
decreased incidence of cardiovascular events among "high-risk" 
patients (P = .06) but not "low-risk" patients (P > .10). 
Patients in the control group were not allowed to con¬ 
tinue untreated when their blood pressure exceeded the study 
limits established for mild hypertension. During the 5 year 
trial period, 65 untreated men (17%) required pharmacologic 
intervention. Investigators tried to minimize the occurrence 
of side-effects by employing a protocol with inherent flexibility, 
and they reported finding "no serious drug-induced" disease. 
However, there was a significantly greater proportion of patients 
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in the treated population with complaints of drowsiness, fatigue, 
impotence, and/or gout. Indeed, methyldopa caused drowsiness and 
fatigue in 41% of the patients and so was substituted for by 
propranolol. The overall drop-out rate was only 1,7%, 
The authors of this study concluded: 1) that anti¬ 
hypertensive treatment confers significant protection against 
"pressure-related" events (e.g., stroke, congestive heart failure, 
left ventricular hypertrophy); 2) there was no protection against 
atherosclerotic coronary artery disease; 3) there was no effect 
on overall cardiovascular morbidity; and 4) patients at "high- 
risk" (diastolic blood pressure > 100 mmHg) at the time of entry 
probably benefited from therapy. 
Commentary 
This is yet another trial with essentially negative find¬ 
ings as there was no difference between treated and untreated 
patients in the incidence of deaths or overall cardiovascular 
morbidity. The authors' did show a statistically significant 
difference between the compared groups in the incidence of 
"pressure-related" cardiovascular events. However, this distinc¬ 
tion is artificial and really does not provide added information. 
Regardless of the findings for "pressure-related" events, if 
there is no benefit from treatment against overall cardiovas¬ 
cular morbidity, then treatment is not indicated. The 
investigators' nearly significant finding (P = .06) is potentially 
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of great importance, but the design of the trial allowed for 
ample opportunity for bias to influence the results. The major 
defect in the design of the stratified analysis is the non- 
blinded assessment of outcome events as both the physicians arid 
the patient were aware of the assigned treatment. This dis¬ 
regard for double-blind administration of treatment renders 
the assessment of non-fatal outcome events particularly suscep¬ 
tible to bias. 
The design of this trial allows for unequal detection of 
not only non-fatal trial end points but also adverse effects of 
treatment. The adverse effects of treatment were poorly char¬ 
acterized, and their incidence was not discussed other than 
mention of an "increase" in complaints of fatigue, impotence, 
and gout in the treated group. Subjective changes in functional 
capacity or quality of life were not monitored in this study'. 
AUSTRALIAN STUDY (41) 
Summary 
The Australian National Blood Pressure Study was designed 
to detect a 30% reduction in morbidity and mortality over 5 years 
of follow-up in treated patients with asymptomatic mild hyper¬ 
tension. In order to generate a trial population, screening 
centers were established at several locations throughout the 
community including public buildings and places of business. 
Volunteers from the general population between 30-69 years of 
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age had their blood pressure measured. Subjects were eligible for 
admission if their diastolic blood pressure fell between 95-110 
mmHg providing that they had not already been receiving anti¬ 
hypertensive medications. However, an effort was made to exclude 
all people with evidence of end-organ disease (e.g., myocardial 
infarction, angina, stroke, renal failure). Additional exclusion 
factors included: co-existing terminal illness; a primary cause 
of hypertension; or the presence of diabetes mellitus, gout or 
asthma. Of 104,171 volunteers screened, 3931 were randomized, but 
504 subjects were later eliminated from the study because their 
post-randomization diastolic blood pressure fell below the study 
threshold of 95 mmHg making them ineligible to begin treatment 
under the study protocol. The size of the final trial population 
was therefore 3427 or 3.3% of those screened. The characteristics 
of the trial population are provided in Table 2. Patients were 
randomly allocated, with stratification by age and sex, to either 
the active regimen (1721) or the placebo (1706) but treatment was 
administered in a single-blind fashion with patients unaware of 
the treatment they were receiving. The compared groups were well- 
matched at entry. The protocol called for a "stepped care" 
approach so that anti-hypertensive medications could be adjusted 
until blood pressure was brought under control. If participants 
in either group developed and maintained a diastolic blood pressure 
above the threshold of 110 mmHg, these subjects were classified 
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under "pressure limits exceeded", and definitive anti-hypertensive 
treatment was given. This was not considered an outcome event 
and these subjects, 198 in the placebo group and 4 in the actively 
treated group were kept in the study. All subjects were given 
advice on weight, diet, and smoking irrespective of the regimen 
to which they had been randomized. The mean duration of follow¬ 
up was 4 years. During this time, the mean difference in 
diastolic pressure between the treated and untreated groups was 
6 mmHg (see Table 4). 
A wide range of cardiovascular-related outcome events was 
considered and all such events were reviewed by a blinded com¬ 
mittee. The analysis of trial end-points was done in two ways. 
In the "on treatment" approach, account was taken only of those 
trial end-points occuring while subjects were continuing their 
regimen. In the "intention to treat" approach, account was taken 
of all trial end-points regardless of whether or not participants 
had remained on their assigned regimens. In presenting the re¬ 
sults of this RCT, I will focus on the data provided by the 
latter approach for three reasons: 1) the advantages of the 
initial randomization are preserved; 2) the "on treatment" 
analysis ignores a large segment of the study population as over 
one third of the participants prematurely discontinued their 
assigned regimen; 3) Reader et al. (54) have pointed out that 
the "on treatment" analysis was: "based on ’softer’ data as a 
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higher proportion of fatal than non-fatal events occured after 
withdrawal". 
During the course of this trial, there were 26 deaths 
(.8%) with 8 occurring in the experimental group and 18 in the 
compared group. The number of major morbid events was evenly 
distributed between the two groups with an overall incidence 
of 2.4%. Minor events were nearly twice as common (4.8%) and 
were more frequent in the control group (see Tables 5-7). 
The difference between the compared groups only achieved 
statistical significance (P < .05) when all events were consi¬ 
dered together. Over two thirds of all trial end-points were due 
to ischemic heart disease, predominantly non-fatal events, which 
occurred in similar numbers in the active and placebo groups. 
Only preliminary information was provided on the differences 
in attack rates for prognostic subgroups. These comparisons were 
performed using data from the "on treatment" analysis, and the 
numbers of trial end-points were small in some subsets. Treat¬ 
ment appeared to be of most benefit in men and in all subjects 
over the age of 50. Trial end-point rates increased with the 
average diastolic pressure recorded throughout the trial in both 
treated and untreated patients. 
The authors concluded that treatment is efficacious in 
reducing morbidity and mortality secondary to cardiovascular 
disease in patients with asymptomatic mild hypertension. However, 
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they found that the majority of outcome events was related to 
ischemic heart disease where treatment seemed to be of little 
benefit; the investigators suggested that trials with longer 
periods of follow-up might be necessary: 1) a longer period of 
follow-up, with treatment beginning at an earlier age, might 
have a greater chance to influence the natural course of 
ischemic heart disease; 2) an extended period of follow-up 
would allow the occurrence of a sufficient number of events to 
demonstrate therapeutic benefit. They noted that this might 
pose ethical problems, however, given that they considered 
there to be overall benefits of treatment. 
Commentary 
This ambitious study screened over 100,000 people but 
less than 4% were found to be eligible for admission. The target 
population was well-identified — those screened were members 
of the general population between 30-69 years of age. After 
multiple visits, subjects found to have a mean diastolic pres¬ 
sure of 95-110 mmHg were asked to join the study. Variability 
within the trial population was limited by admission and 
rejection criteria designed with the clear intent of excluding 
patients with co-morbid conditions (e.g., diabetes mellitus) or 
evidence of cardiovascular disease. Undoubtedly, these criteria 
were in large part responsible for the small percentage of 
patients admitted to the study. 
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Information detailing the compared regimens was fur¬ 
nished, and treatment was applied in a clinically appropriate 
manner: 1) a "stepped care" approach was employed: 2) irrespec¬ 
tive of the assigned regimen, patients were followed until 
their blood pressure exceeded the defined mild range at which 
point definitive treatment was given; 3) all subjects were 
given advice on weight reduction, diet, and smoking. There 
was random allocation of treatment with stratification by age 
and sex though not by entry blood pressure. This process 
appeared to be reasonably effective as the compared groups were 
well-matched at entry. The fact that over one-third of the 
trial population prematurelv discontinued their assigned regi¬ 
men may have disturbed the even distribution of patients 
achieved by the initial randomization process. More importantly, 
however, this striking inability to maintain patients on study 
protocol brings to light two other serious deficiencies in this 
trial: 
1) In the actively treated group, the premature inter¬ 
ruption of study protocol was most often patient-initiated, yet 
reasons for the discontinuation of active treatment were not 
addressed. In this trial, the adverse effects of treatment 
were altogether ignored; not even were the more readily pre¬ 
dictable short-term side-effects of treatment considered. Adverse 
effects of treatment may have contributed to the withdrawal of 
some of these patients. 
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2) Though not a majority, a large percentage of patients 
who withdrew from the placebo group did so at the suggestion of 
their physician. In a single-blind study, the physician's ob¬ 
jectivity is compromised and this can introduce bias into the 
study both in the performance of the maneuver and in the detec¬ 
tion of outcome vents, particularly the more subjective ones. 
The large number of subjects violating study protocol also 
created problems in interpreting the results, prompting the 
investigators to analyze the data in two ways, the "intention- 
to-treat" approach and the "on treatment" approach. However, 
there are problems with both analyses. (The deficiencies of the 
"on treatment" approach have been previously mentioned.) Though 
the "intention-to-treat" approach preserves the benefits of 
the randomization process, both groups are significantly con¬ 
taminated by patients who have switched treatment. 
The authors did not achieve their goal of demonstrating 
a 30% reduction in morbidity and mortality in treated patients 
with asymptomatic mild hypertension in either of the two analy¬ 
ses. Indeed, the data they provide does not justify their 
conclusion that treatment is efficacious in reducing morbidity 
and mortality in patients with this disorder. The difference 
in deaths was not significant, and major cardiovascular end-points 
were evenly distributed between treated and untreated patients. 
The biggest difference between the compared groups was in the 
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incidence of minor morbid events, and it was only when these out¬ 
come events were considered in the analysis that the overall results 
achieved statistical significance. Morbid events, particularly the 
minor ones, may have been detected unequally however because of 
single-blind observation. 
JAPANESE STUDY (43) 
Summary 
This prospective study was performed to evaluate the effi¬ 
cacy of long-term anti-hypertensive therapy in elderly patients 
with mild hypertension. The subjects screened were residents of 
convalescent homes, and all were over the age of 60. Following 
the discontinuation of any anti-hypertensive medications, serial 
blood pressure readings were recorded, and those patients with 
an average diastolic blood pressure of 90-110 mmHg or an average 
systolic blood pressure of 160-200 mmHg were accepted into the 
trial. Because both the systolic and diastolic pressure were 
incorporated in their definition for mild hypertension, only 56% 
of the study population had a diastolic blood pressure greater 
than 90 mmHg. The mean diastolic pressure for all participants 
was 86 mmHg. Apparently, age and blood pressure were the only 
requirements for admission. Ninety-one patients were selected 
for study — their entry characteristics are provided in Table 2. 
Participants were started on either active treatment (44) or a 
placebo (47) ; the regimen was assigned on the basis of matched 
I 
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pairings which took into account age, sex, and entry blood pres¬ 
sure. Whether treatment was blinded is unclear, however, 
treatment was administered in accordance with a "stepped" 
approach. During the four-year follow-up period, a difference 
in diastolic blood pressure of 7 mmHg was maintained between the 
compared groups (see Table 4). 
Over the course of this study, there were 14 deaths (18%) 
7 in each group. There was one major event (2.3%) in the treated 
group as opposed to 6(12.8%) in the untreated group. Data for 
minor events was not presented (see Table 5-7). Subjects were 
removed from the trial when their blood pressure became elevated 
above 200/110 mmHg. There were 8 such cases — all were in the 
placebo group (19%). Only when these cases were treated as trial 
end-points did the authors find a statistically significant dif¬ 
ference in cardiovascular complications between the compared 
groups. The investigators recorded other non-cardiovascular 
complications during the follow-up period (e.g., malignancies, 
infections, bone and joint diseases). There were 12(32%) such 
events in the experimental group and 17(42%) in the placebo group 
These complications were 2 to 3 times more prevalent than the 
cardiovascular-related complications. Side-effects other than 
asymptomatic biochemical fluctuations (e.g., hypokalemia, hyper¬ 
uricemia) were not monitored in this study. The overall drop-out 
rate was 13% as 6 subjects were lost from both groups. 
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The authors suggested that anti-hypertensive treatment is 
effective in elderly patients with mild hypertension but that 
careful follow-up is necessary not only for cardiovascular com¬ 
plications but for general health considerations as well. A 
statistically significant difference in the number of cardio¬ 
vascular complications was found between the treated and 
untreated groups when the elevation of blood pressure beyond 
study limits was treated as a trial end-point. 
Commentary 
The Japanese trial had substantial problems in design and 
analysis. Few of the experimental principles which have been 
developed to minimize the occurrence of bias in randomized 
clinical trials were adhered to in this prospective study. The 
target population was inadequately described, and the number of 
people screened was not stated. The authors failed to delineate 
the admission/rejection criteria used to select the population 
for study. More importantly, those patients who were admitted 
were insufficiently characterized; key elements such as the 
incidence of demonstrable target organ disease or co-morbid 
risk factors (e.g., diabetes mellitus, hyperlipidemia, smoking) 
were not proved. In addition, some of the patients had a known 
history of hypertension for which they had been receiving treat¬ 
ment, but the overall prevalence or mean duration were not men¬ 
tioned. Collectively, this lack of information makes it 
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difficult to determine how representative the study population is 
of elderly mildly hypertensive patients, and whether the allocation 
process created groups with equal prognostic risk. 
Treatment was assigned on the basis of matched pairings of 
patients. Unlikp a truly random process, this method cannot 
ensure that bias will not take place during the allocation of 
treatment. Though the study was placebo-controlled, no mention 
was made of whether therapy was administered in a double-blind 
fashion. Thus, the detection of outcome events, particularly non- 
fatal ones, may have been somewhat unreliable. The experimental 
regimen utilized a "stepped" approach in which anti-hypertensive 
medications were adjusted according to blood pressure. Regard¬ 
less of the assigned regimen, definitive anti-hypertensive 
treatment was given when the blood pressure exceeded 200/110 mmHg. 
There was no discussion of whether compliance was monitored. 
The investigators observed both cardiovascular-related 
events and non-cardiovascular-related events (e.g., infections, 
psychiatric disorders, cancers, bone and joint diseases). They 
noted a statistically significant difference in cardiovascular- 
related end-points between the compared treatment groups. However, 
this finding is somewhat misleading because in their analysis of 
trial end points, the authors included eight subjects from the 
placebo group who had been started on active treatment in response 
to an elevated blood pressure. When these patients are removed 
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from consideration, there is little difference between the treated 
and untreated groups. In addition, there was a relatively even 
distribution of non-cardiovascular-related events which were two 
to three times more common than cardiovascular-related end-points. 
Possible adverse effects of treatment were not considered in this 
trial. 
The results of this trial would seem to suggest that anti¬ 
hypertensive treatment is not indicated in elderly patients with 
mild hypertension, but rather that careful general medical follow¬ 
up is needed. 
DISCUSSION 
There is a consistent set of methodologic problems in the 
designs of the eight completed randomized clinical trials of mild 
hypertension. These deficiencies involve issues in both internal 
validity and external generalizability and are in large part res¬ 
ponsible for the failure of these studies to provide definitive 
answers for determining which mildly hypertensive patients will 
benefit from therapy. At this point, I would like to briefly 
review these methodologic problems — the purpose of this review 
is not merely to reiterate the methodologic requirements of RCTS 
as stated in the Methods section of this thesis, but rather to 
focus attention on common deficiencies which contribute to the 




A. Research Obj ectives 
Comparison of the eight trials of mild hypertension is made 
difficult by the fact that the research objectives of the individual 
studies were highly variable. The first study, the VA-Cooperative 
Group Study, was designed to determine whether anti-hypertensive 
therapy was effective in reducing cardiovascular-related morbidity 
in mildly hypertensive patients (diastolic blood pressure = 
90-115 mmHg). The findings of this study led to the widely ac¬ 
cepted conclusion that a diastolic pressure of 105 mmHg or greater 
was an indication for life-long pharmacologic intervention. 
Thereafter, research attention shifted to people who were at lower 
risk — those with smaller elevations of diastolic pressure 
(< 105 mmHg) and free of evidence of end-organ disease (e.g., USPH, 
Australian, Oslo trials). The Japanese study was further limited 
in that it was concerned with the efficacy of anti-hypertensive 
therapy in elderly mildly hypertensive patients (> 60 years of age). 
The VA-NHLBI trial was not designed to determine whether 
pharmacologic anti-hypertensive therapy reduced morbidity and mor¬ 
tality in mildly hypertensive patients. Rather, the major purpose 
of this two-year feasibility trial was to determine whether a 
large population of asymptomatic mildly hypertensive patients could 
be identified,.enlisted, and maintained on study protocol for an 
adequate period of follow-up; unfortunately, the full-scale trial 
never followed. Similarly, the intent of the HDFP study was not 
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to determine whether anti-hypertensive treatment was efficacious 
in mildly hypertensive patients, for the findings of earlier 
studies had convinced these investigators that treatment was 
indicated in such patients. Hence, the HDFP trial was designed 
to determine how mildly hypertensive patients could be best 
identified and how anti-hypertensive treatment could then be 
best administered. As a consequence of these different pur¬ 
poses, each of the studies incorporated different features of 
research design. Nevertheless, all studies recorded and 
analyzed their data for the effects of treatment on mortality, 
and all but one study reported data on morbidity. Thus, com¬ 
parisons of the trials and their treatment effects are possible. 
B. Baseline State Considerations 
Insufficient measures have been taken to ensure that the 
effects of treatment were compared in subjects with similar 
risks for suffering morbid events. One of the key elements of 
the prospective randomized clinical trial is the random alloca¬ 
tion of treatment, yet in 2 of the 8 studies, treatment was not 
assigned in a strictly random manner. Thus, allocation bias 
cannot be discounted in these two trials. The efficacy of the 
allocation process, regardless of its nature, has been difficult 
to confirm in each of the studies because identification of the 
study populations has been generally inadequate with insufficient 
attention given to co-morbid risk factors and gradations in the 
severity of hypertensive disease. 
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To ensure further that treatment is compared in patients 
at equal risk, investigators can subdivide the compared popula¬ 
tions into prognostic subgroups. Despite the advantages offered 
by prognostic stratification, only 4 of the 8 studies elected 
to analyze their data in this manner. In those studies which 
did employ this technique, the investigators' abilities to 
effectively stratify their study populations was limited by 
not only inadequate identification of the clinical characteris¬ 
tics, but also the relatively small size of the compared 
populations. Descriptions of populations of mildly hyperten¬ 
sive patients to be studied must be more complete, and new 
indexes for prognostic strata must be developed so that the 
results can be compared within homogeneous strata of "high" 
and "low" risk patients. 
C. Performance of the Therapeutic Maneuver 
In all the phases of the randomized clinical trial, the 
investigators have a responsibility to fulfill the often oppos¬ 
ing principles of scientific validity and clinical applicability. 
In performing the therapeutic maneuver, they must ensure that 
the compared treatments are applied equally and at clinically 
suitable levels of proficiency. In several studies, these prin¬ 
ciples were compromised. All of the studies monitored for the 
primary effect of anti-hypertensive therapy (i.e. changes in 
arterial blood pressure). However, two (see Table 3) of the 
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studies employed clinically inappropriate experimental proto¬ 
cols, since all patients were given the same fixed regimen. 
In addition, ancillary measures (e.g., salt restriction, weight 
reduction) which can potentially play an important role in 
blood pressure reduction (59), were largely ignored with 
five of the trials failing to even mention whether or not 
ancillary measures were employed. 
Another issue has to do with the initiation of treatment 
for patients whose blood pressure rises above pre-defined 
study limits. All of the studies defined a threshold of 
diastolic pressure beyond which any patient would be given 
definitive anti-hypertensive therapy irrespective of their 
assigned regimen. However, this threshold corresponded to the 
upper limit used to define mild hypertension in only half of 
the trials. In four of the studies, subjects in the control 
group were allowed to continue in the trial untreated when 
their blood pressure exceeded the defined mild hypertensive 
range thereby enhancing their risk for suffering a cardiovascular 
event. In addition to being clinically inappropriate, the de¬ 
layed institution of active therapy has the potential for 
magnifying the observed difference in outcome between treated 
and untreated patients. 
D. Selection, Detection, and Analysis of Outcome Events 
The event (s) chosen as the main outcome of a clinical 
trial must be suitably selected to be clinically meaningful, 
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but at the same time statistically countable. Following the 
selection of outcome events, the investigators must then ensure 
that there is equal detection. The design and the analysis of 
the studies performed thus far are better suited to decisions 
in public health (numbers of cardiovascular deaths prevented 
nationwide) than in personal health. While death is the 
"hardest" of end points, the risk of death to the individual 
with mild hypertension is quite small; however, it is more 
likely that he/she will suffer a non-fatal morbid event. Hence, 
non-fatal cardiovascular complications should receive major 
consideration as trial end points for they are more pertinent 
to issues in personal health. However, steps must be taken to 
ensure that these "softer" trial end points are rigorously defined 
so that their detection is reliable and reproducible. 
The detection of outcome events should not be limited to 
only the potential benefits of treatment but rather should 
include possible adverse consequences of treatment. Yet the 
mild hypertension trials display a common lack of concern for 
adverse effects of anti-hypertensive treatment. Only 4 of the 
8 studies looked for short-term side-effects of therapy, and each 
of these four found a significant increase in the treated group. 
None of the studies attempted to determine whether there were 
subjective changes in quality of life or functional capacity, 
nor did any study consider possible side-effects secondary to 
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long-term exposure to anti-hypertensive medications. In screen¬ 
ing for short-term adverse effects of treatment, biochemical as 
well as symptomatic side-effects should be considered. In 
addition, dependable indexes need to be developed so that in¬ 
formation regarding subtle changes in functional capacity and 
quality of life secondary to drug therapy can be quantified. 
The problem of long-term side-effects had not been re¬ 
cognized until recently. They are often unpredictable occuring 
only after years of drug exposure. The ongoing MRC trial has 
issued a report stating that a significant number of treated 
patients developed peripheral vascular disease after two years of 
anti-hypertensive therapy for mild hypertension (62). In 
addition, beta-blocking agents are known to raise serum trigly¬ 
cerides and lower high density lipoproteins (66), effects which 
have been shown to be associated with an increased risk of 
ischemic heart disease (67,68). Information on possible adverse 
effects due to long-term drug exposure is just beginning to 
appear — most likely the risk of adverse effects from chronic 
anti-hypertensive therapy is small but as Oliver has recently 
reminded us: "... the risks involved in correcting risk must be 
compared with the risk of the disease itself" (63). 
As previously mentioned, following the selection of out¬ 
come events, measures must be taken to ensure that outcome is 
equally detected. After developing precise definitions for 
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outcome events, the investigators must see that these definitions 
are applied uniformly to the compared groups. This requires that 
the physician and the patient are unaware of which treatment the 
patient received. In 4 of the 8 trials, this methodologic pre¬ 
caution was not taken (see Table 3). Thus, in these trials, non- 
fatal end-points and the assignment of cause to fatal end-points 
must be viewed as being unreliable as the observers objectivity 
cannot be guaranteed. 
E. Generalizability 
For the results to be clinically meaningful to the prac¬ 
ticing physician, the population selected for study must be 
representative of the general population of mildly hypertensive 
patients. There is evidence, however, that such was not the 
case in these completed trials of mild hypertension. According 
to the United States National Health Survey, approximately 20% 
of the adult population has a diastolic pressure of 90-109 mmHg, 
yet none of the four population-based trials (USPH, HDFP, 
Australian, Oslo) yielded more than 5% of the subjects screened. 
There are two possible explanations. One is that the 20% popula¬ 
tion estimate is muchtoohigh. However, the more likely explana¬ 
tion is that the yield in these studies was low primarily as a 
result of restrictive eligibility criteria which limit the 
available population. The eligibility criteria should not 
serve to exclude patients from a study on the basis of factors 
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which contribute to overall risk for suffering trial end points 
(i.e. cardiovascular disease). This ignores a critical element 
of this disorder, one which makes its study so difficult — 
heterogeneity within the population of mild hypertensives. 
The problem of heterogeneity can be more effectively addressed 
by accepting a wider range of patients into the study who can 
then be stratified into prognostic subgroups as previously 
discussed. When analyzing the results, outcome can be compared 
across these prognostic subgroups, thus enhancing our chances of 
identifying those mildly hypertensive patients who will benefit 
from anti-hypertensive therapy. 
With these methodologic deficiencies in mind, I would 
now like to quickly review the evidence which has been gathered 
to date looking first at mortality alone and then at all trial 
end points. 
A. Mortality 
Seven of the eight completed trials of mild hypertension 
failed to find clinically substantial or statistically significant 
differences in the number of deaths between treated and untreated 
patients. Only one study, the HDFP trial, found a significant 
reduction in the number of deaths in a group of patients who had 
uniformly received anti-hypertensive therapy with rigorous follow¬ 
up. Subjects in the compared group were referred to their usual 
source of medical care, and many of these patients received 
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anti-hypertensive treatment. As such, this study was not de¬ 
signed to determine whether anti-hypertensive treatment is 
efficacious in mildly hypertensive patients, but rather to 
determine how these patients could best be identified and 
maintained on treatment for an extended period of time. Hence, 
this study essentially compared two health care delivery sys¬ 
tems, and the investigators concluded that patients who received 
systematic anti-hypertensive therapy with frequent follow-up 
fared better than patients who received medical care that was 
customarily available in the community. But how can the sta¬ 
tistically significant finding for all-cause mortality in this 
trial be reconciled with the negative findings of the seven other 
study, especially when the mean difference in diastolic blood 
pressure maintained between the compared groups was among the 
lowest of any of the eight trials (5 mmHg)? I have proposed two 
possible explanations: 1) The experimental group was at lower 
risk at baseline due to ineffective randomization. It is difficult 
to determine what extent this was a factor because the study popu¬ 
lation was inadequately described. 2) Those patients in the ex¬ 
perimental group received superior general medical care. Due to 
the design of this study, the effects of general medical care on 
the one hand, and pharmacologic anti-hypertensive therapy on the 
other, cannot be distinguished. The authors tried to make a 
distinction on the basis of cause-specific mortality — they 
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noted a 26% reduction in cardiovascular-related deaths in patients 
receiving "Stepped Care" as opposed to only a 13% reduction in 
non-cardiovascular-related deaths. There are several problems with 
their argument. Assuming that their findings with regard to 
cause-specific mortality are correct, one is still unable to at¬ 
tribute the difference in cardiovascular-related mortality to 
anti-hypertensive therapy alone. Indeed, the difference in non¬ 
card iovascular deaths argues to the point that subjects in the 
"Stepped Care" group were healthier at baseline and/or received 
better general medical care. A separate issue has to do with 
scientific validity. There was ample opportunity for bias to 
influence cause-specific mortality despite the fact that all 
findings were reviewed by a blinded committee. The decisions 
as to cause of death were made solely on the basis of death 
certificates. The information on these death certificates was 
supplied by the physicians who had been providing care for these 
patients, and the physicians were not blinded as to treatment. 
It should be noted that one other study, the VA-Cooperative 
Group trial, also found a statistically significant difference 
in cardiovascular-related mortality. This trial also had defici¬ 
encies in assigning cause of death. Further methodologic defici¬ 
encies of this study will be reviewed shortly in the discussion 
of all outcome events which follows. 
B. All Outcome Events: Mortality and Morbidity 
The HDFP study did not attempt to evaluate the efficacy of 
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anti-hypertensive treatment in the prevention of cardiovascular- 
related morbidity (i.e. non-fatal events). For the seven re¬ 
maining trials, the incidence of non-fatal cardiovascular events, 
major and minor, ranged from a high of 19.6% in the VA- 
Cooperative Group study to a low of 1% in the VA-NHLBI study. 
Five of the seven trials (USPH, VA-NHLBI, Chelmsford, Oslo, 
Japanese) found no difference between treated and untreated 
patients in the incidence of non-fatal trial end-points. 
In the VA-Cooperative Group study, a significant reduc¬ 
tion in cardiovascular end points (fatal and non-fatal) was 
found. This was the first study of "mild hypertension", and 
of all the studies it showed the greatest difference in morbidity 
between treated and untreated patients. However, the benefits 
of treatment were not evenly distributed across the trial popu¬ 
lation. Indeed, there appeared to be less benefit from treat¬ 
ment in the group of patients with an entry diastolic pressure 
of 90-104 mmHg (a range which more closely approximates the 
current concensus of opinion for "mild hypertension"). In 
addition, this study population was far from being asymptomatic. 
Well over 50% of the subjects had evidence of target-organ 
damage at the time of entry — this undoubtedly contributed to 
the high incidence of trial end points seen in this study. The 
fact that patients in the placebo group were allowed to continue 
in the trial until their diastolic blood pressure exceeded 
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124 mmHg could have contributed substantially to the difference 
in cardiovascular end points observed between the compared groups 
The investigators of the Australian study did not find 
a statistically significant difference between treated and un¬ 
treated patients in the number of non-fatal end-points. 
However, they noted that when all outcome events were considered, 
there was a significant reduction of trial end-points in the 
treated group. The biggest difference was in the incidence of 
minor morbid events, and as previously discussed, this finding 
may be unreliable because there may have been unequal detection 
of these events due to a failure to blind the physicians. 
It is important to note that even in the three studies 
(VA Cooperative Group study, Australian study, HDFP study) which 
have claimed to find a statistically significant difference in 
mortality and/or morbidity between treated and untreated patients 
nowhere has it been shown that patients less than 50 years of 
age benefit from treatment. 
CURRENT POLICY AND CONCLUSIONS 
Based primarily on the findings of the HDFP study, The 
Joint National Committee for the Detection, Evaluation, and 
Treatment of High Blood Pressure issued a policy statement in 
1980 on the management of mild hypertension which stated in part: 
"Although reduction in overall mortality has not yet 
been demonstrated in patients below the age of 50, 
treatment of these patients reduced the incidence of 
such hypertensive complications as stroke, congestive 
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heart failure, left ventricular hypertrophy, and a 
progressive increase in blood pressure. It is 
therefore reasonable to lower blood pressure even 
in uncomplicated mild hypertension by pharmacologic 
and non-pharmacologic means." (55) 
In a follow-up statement, Dr. Robert Levy, Director of the 
National Heart, Lung, and Blood Institute, has commented: 
"... some 60 million Americans are at risk due to 
hypertension and [they] can benefit from therapeu¬ 
tic control. No sustained elevation above 140/90 
can be casually dismissed as needing no interven¬ 
tion, and any elevation that is treated should be 
treated to achieve a specific goal of blood pres¬ 
sure. It has been estimated that between 60,000 
to 80,000 premature deaths each year may be averted 
if these recommendations [of the Joint National 
Committee] are followed." (56) 
Despite these policy statements, I conclude that the evi¬ 
dence available to date does not justify a uniform policy towards 
the treatment of mild hypertension. The major reason that 
answers have not been immediately forthcoming has to do with the 
difficult nature of the problem. Mildly hypertensive patients 
are at low risk and follow very different courses ultimately 
experiencing highly variable outcomes. The randomized clinical 
trials which have been employed to assess the problem of mild 
hypertension have inherent conflicts. Investigators must ensure 
that their trials are scientifically valid, feasible, and clini¬ 
cally applicable all at the same time. I contend that a common 
flaw in the studies performed thusfar is the sacrifice of clini¬ 
cal relevance in favor of scientific validity and feasibility 
(e.g., type of patients selected for study, types of outcome 
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events considered, and the consistent omission of possible 
adverse effects of treatment), and therefore would suggest that 
future studies be designed and performed with more attention 
paid to clinical applicability. 
Unless we can better define those mildly hypertensive 
patients who are most likely to benefit from treatment, we may 
be needlessly committing millions of patients to the inconveni¬ 
ence and expense as well as yet poorly defined risks of life-long 
anti-hypertensive therapy. Indeed, as physicians we must ask 
whether a uniform policy of treating all mildly hypertensive 
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TABLE 4 
MONITORING OF BLOOD PRESSURE AND STUDY PARTICIPANTS 
ACCORDING TO TREATMENT ASSIGNMENT 
Target Blood Change in Change in 
Name of Pressure SBP DBP 
Trial (mmHg) (mmHg) (mmHg) 
Veterans Admin. 
T ? -27 -17 
C - 4 + 1 
U.S.P.H. 
T ? -16 -10 
C 0 0 
T < 85 ? -12 
V.A.-N.H.L.B.I. 
C ? - 5 
T ? ? ? 
Chelmsford 
C 7 7 
H.D.F.P. 
T < 90 7 -10 
C ? - 5 
Oslo 
T < 90 -17 -10 
C 0 0 
Australian 
T < 90 7 -12 
C 7 - 7 
Japanese 
T ? - 9 0 




























Note: T = treated group: C = control group 
*Drop-outs are those patients who were prematurely withdrawn from the trial or 
otherwise lost to follow-up. 
Although only ~ 2% of the study population was lost to follow-up, it should be 
noted that 34% of treated subjects and 37% of control subjects prematurely dis¬ 
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Veterans Admin. 4.8% (9) 14.4% (23) - 9.6 
U. S . P. H. 3.1% (6) 3.6% (7) - 0.5 
V.A.-N.H.L.B.I. 0.4% (2) 0.6% (3) - 0.2 
Chelmsford 5.4% (6) 13.2% (16) - 7.8 
H.D.F.P. ? ? — 
Oslo 2.0% (8) 3.2% (12) - 1.2 
Australian 2.4% (41) 2.4% (41) 0 
Japanese 2.3% (1) 12.8% (6) -10.5 
*Major morbidity includes the following non-fatal cardiovascular 
complications: myocardial infarction, cerebrovascular accidents, 











(No.) Difference (T-C) 
Veterans Admin. ? 7 — 
U.S.P.H. 9.8% (19) 20.9% (41) -11.1 
V.A.-N.H.L.B.I. Higher in Treated Groupi 
Chelmsford ? 7 — 
H.D.F.P. ? 7 — 
Oslo 1.6% (6) 3.2% (12) - 1.6 
Australian 4.2% (72) 5.4 % (92) - 1.2 
Japanese 7 7 — 
*Minor morbidity includes the following non-fatal cardiovascular 
complications: transient ischemic events, left ventricular 
hypertrophy, cardiomegaly (determined radiographically), retino¬ 
pathy, and evidence of renal failure (elevated serum creatinine). 




RE-ANALYSIS OF OUTCOME EVENTS: 









Quality of Life 
Functional Capacity 
Veterans Admin. 11.7% (22) 6.3% (10) + 5.4% Not Measured 
U.S.P.H. 9.8% (19) 2.0% (4) + 7.8% Not Measured 
V.A.-N.H.L.B.I. -300% (1479) -140% (701) + 160% Not Measured 
Chelmsford Not Measured Not Measured 
H.D.F.P. Not Measured Not Measured 
Oslo Measured but Data Not Provided Not Measured 
Australian Not Measured Not Measured 
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